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Abstract
Objective We examined long-term risk of cancer in
women exposed to diethylstilbestrol (DES) in utero.
Methods A total of 12,091 DES-exposed women in the
Netherlands were followed prospectively from December
1992 till June 2008. Cancer incidence was assessed through
linkage with the Dutch pathology database (PALGA) and
the Netherlands Cancer Registry and compared with the
Dutch female population.
Results A total of 348 medically verified cancers occur-
red; median age at end of follow-up was 44.0 years. No
overall increased risk of cancer was found (standardized
incidence ratio [SIR] = 1.01; 95% confidence interval
[CI] = 0.91, 1.13). The risk of clear cell adenocarcinoma
of the vagina and cervix (CCA) was statistically signifi-
cantly increased (SIR = 24.23; 95% CI = 8.89, 52.74);
the elevated risk persisted above 40 years of age. The risk
of melanoma diagnosed before age 40 was increased
(SIR = 1.59; 95% CI = 1.08, 2.26). No excess risks were
found for other sites, including breast cancer.
Conclusions Except for an elevated risk of CCA, per-
sisting at older ages, and an increased risk of melanoma at
young ages, we found no increased risk of cancer. Longer
follow-up is warranted to examine cancer risk at ages when
cancer occurs more frequently.
Keywords Diethylstilbestrol  Estrogens  Prenatal
exposure delayed effects  Adverse effects  Cancer risk
Introduction
Diethylstilbestrol (DES) is a synthetic estrogen that was
prescribed to several millions of pregnant women worldwide
from the late 1940s to the early 1970s, in order to prevent
miscarriages and other pregnancy complications [1, 2].
Among women exposed prenatally to the drug, several
adverse health effects have been observed before age 30,
such as clear cell adenocarcinoma of the vagina and cervix
(CCA) and reproductive tract abnormalities [3, 4]. These
findings raised concern about potential other long-term
health effects. In prenatally DES-exposed mice, similar
genital tract alterations were found, including vaginal ade-
nocarcinomas and adenosis [5]. In addition, DES-exposed
mice developed uterine tumors [5].
Molecular mechanisms are still unclear, but results from
animal studies suggest that DES exposure in utero might lead
to a persistent overexpression of protooncogenes that are
associated with increased proliferation (c-jun, c-fos, c-myc)
or decreased apoptosis (bcl-2, bcl-x), resulting in unregu-
lated cell growth and carcinogenesis (see review [6]). In
addition, growth factor genes (like EGF, TGF-a) have been
shown to be overexpressed after in utero exposure to DES
[7]. Also other estrogen responsive genes, like the lactoferrin
gene, are induced by DES exposure (see review [6]).
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In humans, long-term cancer risk in DES daughters has
only been studied in the National Cancer Institute (NCI)
DES Follow-up Study [8]. With a median age of 49 at the
end of follow-up, this study revealed no excess risks for
cancer except for CCA and breast cancer after age 40.
Risks for squamous cell cervical cancer and melanoma
could not be evaluated, because agreement between self-
reported cancers and medical verification was poor and
medical verification data were incomplete.
We report on the first European study of cancer risk in a
large cohort of 12,091 DES-daughters, with long-term and
complete follow-up. Cancer incidence was ascertained
through linkages with the population-based Netherlands
Cancer Registry (NCR) and the Dutch nationwide pathol-
ogy database (PALGA) [9]. Since all cancers were medi-
cally verified, this study is the first one to report on the
risks of squamous cell cervical cancer and melanoma.
Materials and methods
Study population
The DES-net project is a nationwide prospective follow-up
study of 12,091 Dutch DES daughters, identified through
the registry of the Netherlands DES Center. This registry
was established in 1992, in order to deal with future health
claims. All DES daughters were advised to register, both
individuals with and without health problems at time of
registration. Documented DES exposure was not necessary
at the time of registration. Median age of the DES
daughters at time of registration was 29.
From March 2000 till December 2004, 13,113 women
received a 16-page mailed questionnaire on risk factors for
hormone-related cancers and medical history (Fig. 1). The
questionnaire included an informed consent form to grant
permission for abstracting data from their medical records
and population-based disease registries. Also, women were
asked to provide a copy of their documented DES expo-
sure. In case no copy was available, the mother was asked
to give permission to have her medical record traced by the
researchers. Non-responders were sent a reminder after
2 months and a second reminder after 6 months. The final
response rate to the questionnaire was 60%.
The study was approved by the Medical Ethical Committee
of the Netherlands Cancer Institute and the Surveillance
Committees of PALGA and the NCR.
Assessment of cancer incidence and death
Cancer incidence was assessed through linkage with PALGA
and NCR, which both have nationwide coverage since
1989 and 1991, respectively. The Surveillance Committees
granted us permission to link both responders and non-
responders under strict privacy procedures, while we exclu-
ded 202 women who had refused. Linkage information
was complete for 12,251 women (Fig. 1). After linkage,
information was provided on date of diagnosis, type of tumor,
and morphology. All tumors were coded according to the
International Classification for Diseases, 10th revision. Vital
status was obtained by linkage with the Dutch Office of Death
Registry (CBG), updated till October 2007. A total of 128
women died during follow-up, of whom 54 died of cancer.
Classification of DES exposure for women
with questionnaire data
Documented DES exposure was available for 881 subjects
(Table 2). For the majority of our subjects, no documented
DES exposure was available. For sensitivity analyses, we
used as surrogates of DES exposure medically verified
DES-related reproductive tract abnormalities (such as
adenosis, squamous cell metaplasia occurring in the vagina
or in an extensive area of the portio (more than 75%), cox
comb, vaginal ridges, T-shaped uterus). Adenosis and
squamous cell metaplasia were ascertained by colposcopy.
Furthermore, we assigned women to ‘suspected DES-
exposed’ in case women reported in the questionnaire
threatened or prior bleeding or prior pregnancy loss as
indications for DES usage by their mother, since it has been
observed that these indications are strongly associated with
documented DES exposure [10]. Finally, we distinguished a
category of women who had been frequently screened (3 or
more cervical Pap smears before age 30 or 2 or more vaginal
smears before age 50), with exclusion of diagnostic smears.
Pap smears before age 30 occur very infrequently in the
DES daughters registered at the DES Center Utrecht 
Active refusal, n = 642
Cohort, n = 12,471 
 Returned questionnaire, n = 7,925 
 No questionnaire returned, n = 4,546 
Missing date of birth, n = 18 
Active refusal for linkage, n = 202  
Linkage to Pathology registry and  
Netherlands Cancer Registry, n = 12,251 
Cancer before start follow-up, n = 160 
Analytical cohort, n = 12,091
n = 13,113 mailed questionnaires 
Fig. 1 Response rates of eligible cohort of DES daughters
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general population as the Dutch national screening surveil-
lance program starts at age 30. In DES daughters, however,
Pap smears before age 30 do occur since they are advised to
have a yearly gynecological exam during the first 5 years of
DES surveillance, including vaginal and cervical smears.
Therefore, having had 3 or more Pap smears before age 30
was considered a valid indicator of suspected DES exposure
in the Netherlands.
Validation of DES exposure for women
with questionnaire data
For 115 subjects, we compared self-reported DES exposure
with the information in prenatal records in four hospitals
with preserved historical medical archives.
Statistical analyses
Women with cancer diagnosed before the start of follow-up
(n = 160) were excluded from analyses, among whom
were 53 patients with CCA. A total of 12,091 women were
included in the analyses. Follow-up started at the date of
registration at the DES Center and ended on June 30, 2008,
the date of first cancer diagnosis, or death, whichever came
first. We excluded 2 second primary tumors that were
probably related to cancer treatment (1 squamous cell
cervical cancer after treatment for cervical adenocarci-
noma; 1 squamous cell vaginal cancer after treatment for
vaginal adenocarcinoma).
Standardized Incidence Ratio’s (SIRs) were calculated
to compare the observed cases in our study with the
expected number in the general population, based on age-,
sex-, and calendar period-specific incidence rates from the
NCR. The 95% confidence intervals (95% CI) were cal-
culated assuming a Poisson distribution [11].
We also calculated risks for women stratified according
to the availability of questionnaire data, age, type of DES
confirmation, medical indication for DES use, parity,
maternal age of DES mother, education, and duration of
index pregnancy.
As reference for the stage distribution of melanoma, we
used the age-specific stage distribution in the general
female population in the period 2003–2007.
To test for heterogeneity in the SIRs between strata, the
chi-square distribution was applied [11].
We used SPSS statistical software (SPSS Inc., Chicago,
IL).
Results
The majority of the DES daughters were born between
1961 and 1970, with no differences between women with
and without a questionnaire (Table 1). Ninety-three percent
of the women registered in 1992. The median age at the
end of follow-up was 44.3 years in the questionnaire group
and 43.3 years in the group without questionnaire.
Twelve percent of the DES daughters with questionnaire
data had documented DES exposure, 22% had medically
verified DES-associated reproductive tract abnormalities,
and 26% had a history of frequent vaginal or cervical
screening (Table 2). Habitual abortion was the most fre-
quently self-reported medical indication for DES usage by
the mother (50%), followed by threatened abortion (25%)
or the combination of both (17%). DES daughters were
more often highly educated (college or university) com-
pared to women in the Dutch female population (38 and
25%, respectively, reference data not in the table). Twenty-
eight percent of the women had overweight or were obese
(compared to 34% in the general female population).
Thirty-three percent of the DES daughters above 40 years
of age (as a proxy for the end of a woman’s fertile lifespan)
were nulliparous, compared to 17% of the Dutch popula-
tion in the same age category (reference data not shown).
Overall cancer risk was not increased in DES daughters
compared to the general population (SIR = 1.01; 95%
CI = 0.91, 1.13) (Table 3). The SIR for CCA of the vagina
and cervix was statistically significantly increased
(SIR = 24.23; 95% CI = 8.89, 52.74). No association for
breast cancer was observed (SIR = 1.05; 95% CI = 0.90,
1.23). The risk of squamous cell cancer located in the
vagina or cervix was non-significantly decreased compared
to the general population (SIR = 0.64; 95% CI = 0.31,
Table 1 Baseline characteristics of Dutch DES daughters
(n = 12,091) according to type of response
Questionnaire
(n = 7,589)
Without questionnaire
(n = 4,502)
No. of women % No. of women %
Year of birth
B1955 968 13 557 12
1956–1960 1,731 23 840 19
1961–1965 1,852 24 1,095 24
1966–1970 2,139 28 1,280 28
[1970 899 12 730 16
Age at end of follow-up
\40 2,103 28 1,425 32
40–49 3,853 51 2,231 50
50? 1,633 22 846 19
Year of registration
1992 7,052 93 4,139 92
1993–1995 304 4 244 5
1996–2000 200 3 65 1
2001–2005 33 0 54 1
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1.17). A significantly decreased risk was observed for lung
cancer (SIR = 0.54; 95% CI = 0.27, 0.96). No statistically
significant findings were observed for other types of
cancer. Similar cancer risks were seen in the subgroup of
women with questionnaire data, except for a statistically
significantly increased risk of cancer of the placenta
(chorioncarcinoma) (SIR = 11.41; 95% CI = 1.38, 41.21)
based on two cases. Risk was similar when we restricted
the analyses to women with questionnaire data.
Within the group with questionnaire data, we were able
to stratify according to confirmation of DES exposure
(Table 4). The risks of CCA and vagina cancer were
strongly elevated in all strata, though the SIR estimates for
CCA was highest in the group confirmed by medical file
(SIR = 109.9; 95% CI = 12.3, 396.79). The observed
events of melanoma occurred in two strata and both
showed similarly elevated SIRs. The risk for breast cancer
was highest in the group with the lowest level of DES
confirmation (SIR = 1.94; 95% CI = 0.93, 3.57).
When we compared self-reported DES exposure with
the information in prenatal records DES exposure was
confirmed in 53 records of the 70 subjects (76%), in 15
records neither DES nor other medication was recorded
(21%), and in 2 records another drug was mentioned (3%)
(Table 5).
Table 6 shows the association between DES exposure
and risk of cancer stratified according to age at diagnosis.
The risk of melanoma, diagnosed before age 40, was sta-
tistically significantly increased (SIR = 1.59; 95%
CI = 1.08, 2.26), but no increased risk after age 40 was
detected (Table 6). The elevated risk at young ages did not
seem to be attributable to detection bias, because the stage
distribution was comparable with the general population
(v2 1.94, p = 0.75 and v2 5.59, p = 0.23, for ages\40 and
40?, respectively) (Table 1, supplement). CCA risk
remained elevated at ages above 40 (SIR = 32.89; 95%
CI = 3.98, 118.76). The decrease in lung cancer risk was
most pronounced above 40 years of age, but based on eight
cases only. For the other types of cancer, no differences
between age strata were observed.
Four CCA patients were diagnosed in the age category
30–39 years and two CCA patients between the ages of 40–
49 years (Table 2, supplement). The incidence rates for
CCA in women aged 30–39 and 40–49 were 0.05 and 0.04
per 1,000 women-years, respectively. Among the five CCA
patients with medical information, one case had a con-
firmed history of adenosis. One patient had a younger sister
with CCA (no participant, diagnosed at age 23 and
deceased at age 25). All CCA patients diagnosed
prospectively were still alive at the end of our follow-up.
Discussion
In this first European cohort study of cancer risk in DES
daughters, no overall increased cancer risk was observed
Table 2 Baseline characteristics of DES daughters with question-
naire data
Questionnaire
(n = 7,589)
No. of women %
DES confirmation
Medical file mother 881 12
DES-related reproductive tract abnormalities 1,648 22
History of frequenta vaginal screening (before
age 50) or frequenta cervical screening (before
age 30)
1,983 26
No information available 3,077 40
Medical indication DES use mother
Both threatened and habitual abortion 1,310 17
Threatened abortion only 1,902 25
Habitual abortion only 3,827 50
Diabetes 9 0
Premature delivery, uterus problems 34 0
Other problems index pregnancy 36 0
History of pregnancy problems (other than abortion) 153 2
No obvious medical indication (prevention) 94 1
Unknown 224 3
Highest educational level
Primary school 952 13
Secondary school 3,617 48
College or university 2,846 38
Unknown or missing 174 2
Body mass index, kg/m2
\20 939 12
20–24 4,336 57
25–29 1,571 21
30? 557 7
Unknown or missing 186 2
Parityb
Yes 1,360 66
No 680 33
Unknown or missing 34 2
Maternal age (DES mother)
\25 1,141 15
25–29 2,604 34
30–34 2,193 29
35? 1,481 20
Unknown or missing 170 2
a Frequency of screening: two or more vaginal smears before age 50 or
three or more cervical smears before age 30
b Among n = 2,074 women older than 40 at time filling in the
questionnaire
1002 Cancer Causes Control (2010) 21:999–1007
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compared to the general population. The risk of CCA
remained increased after age 40. Neither overall breast
cancer risk was increased, nor risk above age 40. We found
an elevated risk of melanoma before age 40. The risk of
lung cancer was decreased.
A unique feature of this study is the large study size and
the almost complete long-term follow-up for cancer. Also,
all cancers were medically verified. However, a drawback
of our study is that the majority of participants had no
documented DES exposure. Nevertheless, we think that the
assumption is justified that the majority of our subjects was
indeed exposed to DES, for the following reasons. First, in
our validation study self-reported DES exposure was con-
firmed in 53 prenatal records (76%), whereas in 15 records
neither DES nor any other medication was recorded (21%).
It is still possible that in the latter cases DES was
prescribed by the general practitioner rather than the
gynecologist. In the Netherlands, pregnancies have always
been under the surveillance of general practitioners or
midwives. DES was also prescribed by general practitio-
ners but their records are notoriously hard to trace.
Therefore, we estimate that the misclassification with
regard to DES exposure is probably higher than 3% but
certainly lower than 24%. Second, stratification according
to levels of confirmation of DES exposure did not result in
different conclusions (Table 4), whereas more uncertainty
about DES exposure might have led to more bias to the
null. Finally, the proportion of women doubting their DES
exposure was higher among women who did not respond to
the questionnaire. Although, in general, the SIRs were
slightly higher in the questionnaire group, these differences
were not statistically significant (Table 3).
Table 3 Risk of cancer among DES daughters, for all women and women with questionnaire data onlya
Type of cancer All participants
n = 12,091
180,941 women-years
With questionnaire data only
n = 7,589
113,845 women-years
Obs Exp SIR 95% CI Obs Exp SIR 95% CI
Total cancerb,c 348 343.3 1.01 0.91–1.13 217 219.8 0.99 0.86–1.13
Breast 165 156.5 1.05 0.90–1.23 112 100.7 1.11 0.92–1.34
Cervix (all morphologies) 15 20.4 0.74 0.41–1.21 10 13.0 0.77 0.37–1.42
Vagina (all morphologies) 6 0.4 16.42 6.02–35.74 5 0.2 21.51 6.98–50.21
Vagina and cervix 21 20.8 1.01 0.63–1.55 15 13.2 1.13 0.64–1.87
Clear cell adenocarcinoma 6 0.3 24.23 8.89–52.74 5 0.2 32.02 10.38–74.71
Squamous cell carcinoma 10 15.7 0.64 0.31–1.17 7 10.0 0.70 0.28–1.44
Adenocarcinoma 4 3.8 1.06 0.29–2.71 3 2.4 1.25 0.26–3.65
Adenosquamous carcinoma 1 0.7 1.39 0.04–7.76 0 0.5
Vulva 2 1.6 1.27 0.15–4.59 1 1.0 0.99 0.03–5.51
Corpus uteri 9 7.1 1.27 0.58–2.41 4 4.5 0.88 0.24–2.26
Ovaryc 10 10.8 0.92 0.44–1.7 6 6.9 0.87 0.32–1.88
Placenta 2 0.3 7.10 0.86–25.64 2 0.2 11.41 1.38–41.21
Lungc 11 20.4 0.54 0.27–0.96 5 13.2 0.38 0.12–0.89
Melanomac 48 35.3 1.36 1.00–1.8 26 22.4 1.16 0.76–1.7
Colon, rectum, anus 15 17.6 0.85 0.48–1.41 9 11.2 0.80 0.37–1.53
Thyroid 6 6.5 0.92 0.34–2.01 4 4.11 0.97 0.26–2.49
Hodgkin lymphoma 3 3.6 0.84 0.17–2.47 1 2.2 0.45 0.01–2.53
Non-Hodgkin lymphoma, immunoproliferative
disease
8 8.3 0.96 0.42–1.9 6 5.3 1.13 0.42–2.47
Brain 8 6.3 1.28 0.55–2.52 5 4.0 1.26 0.41–2.94
Leukemia 3 5.7 0.52 0.11–1.53 3 3.6 0.83 0.17–2.42
a SIR, Standardized incidence ratio, defined as observed number of cancers compared to the expected number of cancers in the general
population with the same age; 95% CI = 95% confidence interval based on a Poisson distribution, obs = observed number of cases;
exp = expected number of cases
b 27 cancers included in total cancer rate but not included in table: Lip (1), Tongue (1), Mouth (2), Salivary glands (1), Stomach (3), Anus (1),
Pancreas (2), Larynx (1), Trachea (1), Sarcoma (2), Skin, squamous cell (9), Mesothelioma (1), Kidney (1), Bladder (2), Eye (1), Central Nervous
System (1), Plasma cell tumor (1), Unknown or ill defined (6)
c Eight secondary tumors were included: Lung (2), Sarcoma (1), Melanoma (1), Skin, squamous cell (1), Ovary (1), Central nervous system (1),
Non-Hodgkin lymphoma (1)
Cancer Causes Control (2010) 21:999–1007 1003
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Furthermore, women may have registered at the
Netherlands DES Center because of gynecological
complaints, although women without health problems at
time of registration were especially encouraged to register.
Since we prospectively followed all women from time of
registration, all cancer diagnoses prior to registration were
not included in our analysis. However, our results might
still be biased if health problems were related to future
cancer risk (both bias to or away from zero). In a sensi-
tivity analysis, we excluded the first follow-up years in the
analyses, to adjust for signs and symptoms of disease at
time of registration, with similar results.
It is possible that women enrolled into our cohort differ
from the background population of DES daughters. For
instance, with respect to breast cancer nulliparity might
cause such selection bias. As expected, the proportion of
nulliparous women in our cohort was higher than in the
general population (33 vs. 17%, respectively) due to a
higher prevalence of subfertility among DES daughters
compared to the general population [4]. However, if
women registered because of subfertility problems (median
age at registration was 29.1 years), the proportion of nul-
liparous women might be too high, and as a result the risk
of breast cancer in our cohort might be underestimated
during premenopausal years (assuming that the risk of
breast cancer is transiently increased after childbirth, [12]),
and overestimated during postmenopausal years. To
examine whether the SIR of 1.11 (95% CI: 0.92–1.34) for
breast cancer overall was due to nulliparity, we conducted
partially stratified analyses comparing strata of parous and
nulliparous women with the total reference group. The SIR
for breast cancer was 1.19 (95% CI: 0.93–1.49) for parous
and 0.96 (95% CI: 0.66–1.35) for nulliparous women (data
not shown), suggesting that a higher frequency of nulli-
parity did not explain our results.
Another limitation of our study design is the lack of an
internal comparison group, which prevented us from
adjusting for several risk factors for cancer. The stratified
analyses among women with questionnaires showed no
statistically significant differences in cancer risk between
strata of parity, maternal age of DES mother, education,
and duration of index pregnancy (data not shown).
However, residual confounding might still occur, since the
reference group could not be stratified by any confounder
except age and birth cohort. In spite of this, our analyses
suggest that these effects are small.
In contrast to our study, DES exposure in the NCI DES
follow-up study was completely verified. However, inci-
dent cancer cases were obtained by mailed questionnaires
and medical record retrieval for confirmation of self-
reported cancer was incomplete.
With the limitations of our study kept in mind, we found a
highly increased risk of CCA, although somewhat lower thanT
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found in the NCI DES follow-up study (SIR = 24.23; 95%
CI = 6.02, 35.74 and SIR = 39.0; 95% CI = 15, 104,
respectively) [8]. Our SIR estimate does not apply to ages
below 30, which might partly explain the lower estimate. The
CCA incidence rate of 0.05 per 1,000 exposed women aged
30–39 (based on four cases) was similar to the incidence rate
of 0.03 per 1,000 in the NCI study (based on one case in the
same age range) [8]. Our study shows that the CCA risk
remained increased after age 40 (SIR = 32.89; 95%
CI = 3.98, 118.76, incidence rate of 0.04 per 1,000, based on
two cases). Recently, DES-associated CCA patients up to age
55 have been added to the Registry for Research on Hormonal
Transplacental Carcinogenesis, and a possible increase in
incidence at age C40 years has been suggested (http://obgyn.
bsd.uchicago.edu/registry.html). The cumulative incidence
rate for exposed women ages 30–44 years in our study was 0.8
per 1,000 women. Combined with the cumulative incidence
rate in the Dutch CCA registry of 1.5 per 1,000 women
before age 30 (personal communication Jos van Dijck,
Comprehensive Cancer Centre East), we calculated an abso-
lute risk of 2.3 CCA cases per 1,000 DES daughters by age 44
(compared to 1.6 per 1,000 DES daughters by age 39 in the
NCI DES follow-up study).
Trichopoulos et al. hypothesized that prenatal factors
associated with high endogenous estrogen levels in utero
might increase the risk of breast cancer [13]. In the NCI
study, the overall risk for breast cancer was not increased,
comparing DES exposed to unexposed women. However,
at ages C40 and C50 years risks were significantly
increased (incidence rate ratio (IRR) = 1.91; 95%
CI = 1.09, 3.33 and IRR = 3.00; 95% CI = 1.01, 8.98,
respectively) [14]. The increased risks for breast cancer
attenuated when general population data (SEER) were used
as reference, possibly explained by the lower body mass
index of the study population (both exposed and unex-
posed). We used the general population as reference and
found no increased breast cancer risk neither overall, nor
above age 40 (SIR = 1.05; 95% CI = 0.90, 1.23 and
SIR = 1.09; 95% CI = 0.91, 1.31, respectively). Our DES
daughters might differ from the general population with
respect to breast cancer risk factors for which we could not
adjust. However, stratification for educational level, parity,
and maternal age at birth did not alter our results. Another
possible explanation for the inconsistent findings between
our study and the NCI study is chance, because the number
of cases was relatively small in the older age categories.
Also, the misclassification of DES exposure in our study
might have attenuated the risk.
Melanoma risk was statistically significantly increased
among women ages \40 years. In addition, the risk was
Table 5 Validation of self-reported DES exposure in four hospitals
with preserved historical medical archives
Mother self-reported DES exposure,
n = 115
No. medical file available 45 31%
Medical file mother available 70 61%
DES exposure confirmed in medical file
Yes 53 76%
No 15 21%
Other medicine reported 2 3%
Table 6 Risk of cancer among DES daughters by age at diagnosisa
Type of cancer Attained age \40 years of age
119,394 women-years
Attained age C40 years of age
61,547 women-years
Obs Exp SIR 95% CI Obs Exp SIR 95% CI
All types 124 118.8 1.04 0.87–1.24 224 224.5 1.00 0.87–1.14
Breast 42 44.0 0.95 0.69–1.29 123 112.6 1.09 0.91–1.31
Melanoma 31 19.5 1.59 1.08–2.26 17 15.8 1.08 0.63–1.72
Vagina (all morph) 3 0.2 18.02 3.72–52.65 3 0.2 15.08 3.11–44.07
Cervix (all morph) 9 12.95 0.69 0.32–1.32 6 7.4 0.81 0.30–1.76
Vagina and cervix
CCA 4 0.2 21.41 5.81–54.82 2 0.1 32.89 3.98–118.76
Squamous cell 6 9.9 0.60 0.22–1.31 4 5.8 0.70 0.19–1.78
Placenta 2 0.3 7.75 0.94–27.99 0 0.02
Lung 3 3.2 0.94 0.19–2.75 8 17.2 0.46 0.20–0.92
Ovary 4 3.6 1.13 0.31–2.89 6 7.3 0.82 0.30–1.79
Corpus uteri 3 0.9 3.22 0.66–9.41 6 6.2 0.97 0.36–2.12
a SIR = Standardized incidence ratio defined as observed number of cancers compared to the expected number of cancers in the general
population with the same age; 95% CI = 95% confidence interval based on a Poisson distribution; obs = observed number of cases;
exp = expected number of cases
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higher in the total cohort than in the group with ques-
tionnaire data. Possibly, some survival bias may be
present in the questionnaire group as not all melanoma
cases might have survived long enough to be able to
participate to the questionnaire. In the NCI study, mela-
noma risk could not be evaluated because medical veri-
fication of this cancer, and cervical cancer, was
incomplete. Sun exposure and skin type are considered to
be main risk factors, while the role of reproductive and
hormonal factors is controversial [15]. It has been sug-
gested that low parity is associated with an increased risk
[16], but we could not confirm that in our study (data not
shown). Additionally, although this is only circumstantial
evidence, the immune system might be involved. Sup-
pression of immune response in transplantation patients
who receive long-term immunosuppression therapy has
been associated with a higher risk of melanoma [17].
Some studies suggested that DES daughters might be at
higher risk of developing autoimmune diseases [18] or
have an enhanced immune response to different mitogens
[19, 20]. However, the relevance of autoimmune diseases
to melanoma risk is unclear and an enhanced immune
response would probably not be associated with an
increased risk of melanoma. Also it is unlikely that sur-
veillance bias plays a major role, as the stage distribution
of melanoma did not differ between our subjects and the
general population. Since this is the first time that mela-
noma risk was found to be increased in DES daughters,
this result needs to be confirmed by other studies.
The risk of squamous cell cervical cancer was non-
significantly decreased. This is likely due to the high
screening rate among DES daughters, leading to enhanced
detection of precancerous lesions of the cervix. In an
earlier publication, we reported on an increased preva-
lence ratio (PR) of squamous cell cervical cancer among
DES daughters (PR = 5.4; 95% CI = 2.8, 9.5) [21].
However, selection bias could not be ruled out. In the
NCI study, medical verification for cervical cancer was
incomplete and no valid risk estimates were available
[22]. When evaluating cervical cancer risk, one should
also take the number of pre-invasive cervical lesions into
account [23].
In our study, one incident and two prevalent cases of
invasive squamous cell vaginal cancer occurred, while 0.2
case was expected. All cases were reviewed by our
pathologist (HvB). Assuming that these three cases were
the only ones occurring among DES-exposed women in the
Netherlands (alive at the time of registration), we calcu-
lated a life-time prevalence of 3 cases per 40,000 exposed
women (7.5 per 100,000). This prevalence rate was 4 times
as high as the prevalence rate (20-year period) in the
general population in the same age category (1.8 prevalent
cases per 100,000 women, region Comprehensive Cancer
Centre Amsterdam). However, the estimated number of
DES-exposed women in the Netherlands is rather uncertain
and the number of cases is small.
The risk of lung cancer was statistically significantly
reduced in our study. We did not collect information on
smoking habits in our questionnaire. Therefore, we ana-
lyzed smoking behavior of 464 DES daughters that par-
ticipated in a study on IVF treatment effects [24]. DES
daughters smoked less cigarettes compared to the Dutch
female population (source Statistics Netherlands), 13.2 and
15.9 cigarettes per day, respectively, which might explain
our finding.
In conclusion, the results of our study are generally
reassuring except for CCA, with a risk increase persisting
at older ages. The slightly elevated risk of melanoma
before age 40 is remarkable, but needs to be confirmed by
other studies. We did not confirm the increased risk of
breast cancer at older ages, as suggested in the NCI DES
Follow-up study. Since most DES daughters in our cohort
are still relatively young (44.0 years), longer follow-up is
warranted to examine cancer risks at ages when cancer
occurs more frequently.
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